214 related articles for article (PubMed ID: 32238166)
21. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
22. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
Naik S; Nicholas SK; Martinez CA; Leen AM; Hanley PJ; Gottschalk SM; Rooney CM; Hanson IC; Krance RA; Shpall EJ; Cruz CR; Amrolia P; Lucchini G; Bunin N; Heimall J; Klein OR; Gennery AR; Slatter MA; Vickers MA; Orange JS; Heslop HE; Bollard CM; Keller MD
J Allergy Clin Immunol; 2016 May; 137(5):1498-1505.e1. PubMed ID: 26920464
[TBL] [Abstract][Full Text] [Related]
23. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
[TBL] [Abstract][Full Text] [Related]
24. Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody.
Imahashi N; Nishida T; Goto T; Terakura S; Watanabe K; Hanajiri R; Sakemura R; Imai M; Kiyoi H; Naoe T; Murata M
J Immunother; 2015; 38(2):62-70. PubMed ID: 25658615
[TBL] [Abstract][Full Text] [Related]
25. Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients.
Schulze Lammers FC; Bonifacius A; Tischer-Zimmermann S; Goudeva L; Martens J; Lepenies B; von Karpowitz M; Einecke G; Beutel G; Skripuletz T; Blasczyk R; Beier R; Maecker-Kolhoff B; Eiz-Vesper B
J Clin Immunol; 2022 Apr; 42(3):546-558. PubMed ID: 34989946
[TBL] [Abstract][Full Text] [Related]
26. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
27. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
[TBL] [Abstract][Full Text] [Related]
28. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
29. T cells for viral infections after allogeneic hematopoietic stem cell transplant.
Bollard CM; Heslop HE
Blood; 2016 Jun; 127(26):3331-40. PubMed ID: 27207801
[TBL] [Abstract][Full Text] [Related]
30. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.
Keller MD; Darko S; Lang H; Ransier A; Lazarski CA; Wang Y; Hanley PJ; Davila BJ; Heimall JR; Ambinder RF; Barrett AJ; Rooney CM; Heslop HE; Douek DC; Bollard CM
Br J Haematol; 2019 Oct; 187(2):206-218. PubMed ID: 31219185
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection.
Qian C; Wang Y; Cai H; Laroye C; De Carvalho Bittencourt M; Clement L; Stoltz JF; Decot V; Reppel L; Bensoussan D
J Immunother; 2016 Jan; 39(1):27-35. PubMed ID: 26641259
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens.
Albiero E; Amati E; Baumeister E; Einsele H; Grigoleit GU; Rodeghiero F
J Immunother; 2016; 39(9):329-342. PubMed ID: 27631893
[TBL] [Abstract][Full Text] [Related]
33. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.
Abraham AA; John TD; Keller MD; Cruz CRN; Salem B; Roesch L; Liu H; Hoq F; Grilley BJ; Gee AP; Dave H; Jacobsohn DA; Krance RA; Shpall EJ; Martinez CA; Hanley PJ; Bollard CM
Blood Adv; 2019 Jul; 3(14):2057-2068. PubMed ID: 31292125
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.
Zandvliet ML; van Liempt E; Jedema I; Kruithof S; Kester MG; Guchelaar HJ; Falkenburg JH; Meij P
J Immunother; 2011 Apr; 34(3):307-19. PubMed ID: 21389867
[TBL] [Abstract][Full Text] [Related]
35. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
Linn YC; Sundar Raj K; Teo B; Phang CY; Chittezhath M; Koh M
Cytotherapy; 2023 May; 25(5):510-520. PubMed ID: 36882347
[TBL] [Abstract][Full Text] [Related]
36. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
37. Applications of virus-specific T cell therapies post-BMT.
Motta CM; Keller MD; Bollard CM
Semin Hematol; 2023 Jan; 60(1):10-19. PubMed ID: 37080705
[TBL] [Abstract][Full Text] [Related]
38. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
[TBL] [Abstract][Full Text] [Related]
39. A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.
Li Pira G; Ivaldi F; Starc N; Landi F; Rutella S; Locatelli F; Sacchi N; Tripodi G; Manca F
Transfusion; 2014 Dec; 54(12):3145-54. PubMed ID: 25041366
[TBL] [Abstract][Full Text] [Related]
40. Virus-specific T-cell therapies for patients with primary immune deficiency.
Keller MD; Bollard CM
Blood; 2020 Feb; 135(9):620-628. PubMed ID: 31942610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
